Use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in context of COVID-19 outbreak: a retrospective analysis
The possible effects of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) on COVID-19 disease severity have generated considerable debate. We performed a single-center, retrospective analysis of hospitalized adult COVID-19 patients in Wuhan, China, who had d...
| Main Authors: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Springer
2020
|
| _version_ | 1797071159308582912 |
|---|---|
| author | Xu, J Huang, C Fan, G Liu, Z Shang, L Zhou, F Wang, Y Yu, J Yang, L Xie, K Huang, Z Huang, L Gu, X Li, H Zhang, Y Wang, Y Hayden, FG Horby, PW Cao, B Wang, C |
| author_facet | Xu, J Huang, C Fan, G Liu, Z Shang, L Zhou, F Wang, Y Yu, J Yang, L Xie, K Huang, Z Huang, L Gu, X Li, H Zhang, Y Wang, Y Hayden, FG Horby, PW Cao, B Wang, C |
| author_sort | Xu, J |
| collection | OXFORD |
| description | The possible effects of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) on COVID-19 disease severity have generated considerable debate. We performed a single-center, retrospective analysis of hospitalized adult COVID-19 patients in Wuhan, China, who had definite clinical outcome (dead or discharged) by February 15, 2020. Patients on anti-hypertensive treatment with or without ACEI/ARB were compared on their clinical characteristics and outcomes. The medical records from 702 patients were screened. Among the 101 patients with a history of hypertension and taking at least one anti-hypertensive medication, 40 patients were receiving ACEI/ARB as part of their regimen, and 61 patients were on antihypertensive medication other than ACEI/ARB. We observed no statistically significant differences in percentages of in-hospital mortality (28% vs. 34%, P = 0.46), ICU admission (20% vs. 28%, P = 0.37) or invasive mechanical ventilation (18% vs. 26%, P = 0.31) between patients with or without ACEI/ARB treatment. Further multivariable adjustment of age and gender did not provide evidence for a significant association between ACEI/ARB treatment and severe COVID-19 outcomes. Our findings confirm the lack of an association between chronic receipt of renin-angiotensin system antagonists and severe outcomes of COVID-19. Patients should continue previous anti-hypertensive therapy until further evidence is available. |
| first_indexed | 2024-03-06T22:49:15Z |
| format | Journal article |
| id | oxford-uuid:5e42c9c0-47bb-4e52-b0ef-c1f81e4395bf |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T22:49:15Z |
| publishDate | 2020 |
| publisher | Springer |
| record_format | dspace |
| spelling | oxford-uuid:5e42c9c0-47bb-4e52-b0ef-c1f81e4395bf2022-03-26T17:39:29ZUse of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in context of COVID-19 outbreak: a retrospective analysisJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:5e42c9c0-47bb-4e52-b0ef-c1f81e4395bfEnglishSymplectic ElementsSpringer2020Xu, JHuang, CFan, GLiu, ZShang, LZhou, FWang, YYu, JYang, LXie, KHuang, ZHuang, LGu, XLi, HZhang, YWang, YHayden, FGHorby, PWCao, BWang, CThe possible effects of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) on COVID-19 disease severity have generated considerable debate. We performed a single-center, retrospective analysis of hospitalized adult COVID-19 patients in Wuhan, China, who had definite clinical outcome (dead or discharged) by February 15, 2020. Patients on anti-hypertensive treatment with or without ACEI/ARB were compared on their clinical characteristics and outcomes. The medical records from 702 patients were screened. Among the 101 patients with a history of hypertension and taking at least one anti-hypertensive medication, 40 patients were receiving ACEI/ARB as part of their regimen, and 61 patients were on antihypertensive medication other than ACEI/ARB. We observed no statistically significant differences in percentages of in-hospital mortality (28% vs. 34%, P = 0.46), ICU admission (20% vs. 28%, P = 0.37) or invasive mechanical ventilation (18% vs. 26%, P = 0.31) between patients with or without ACEI/ARB treatment. Further multivariable adjustment of age and gender did not provide evidence for a significant association between ACEI/ARB treatment and severe COVID-19 outcomes. Our findings confirm the lack of an association between chronic receipt of renin-angiotensin system antagonists and severe outcomes of COVID-19. Patients should continue previous anti-hypertensive therapy until further evidence is available. |
| spellingShingle | Xu, J Huang, C Fan, G Liu, Z Shang, L Zhou, F Wang, Y Yu, J Yang, L Xie, K Huang, Z Huang, L Gu, X Li, H Zhang, Y Wang, Y Hayden, FG Horby, PW Cao, B Wang, C Use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in context of COVID-19 outbreak: a retrospective analysis |
| title | Use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in context of COVID-19 outbreak: a retrospective analysis |
| title_full | Use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in context of COVID-19 outbreak: a retrospective analysis |
| title_fullStr | Use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in context of COVID-19 outbreak: a retrospective analysis |
| title_full_unstemmed | Use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in context of COVID-19 outbreak: a retrospective analysis |
| title_short | Use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in context of COVID-19 outbreak: a retrospective analysis |
| title_sort | use of angiotensin converting enzyme inhibitors and angiotensin ii receptor blockers in context of covid 19 outbreak a retrospective analysis |
| work_keys_str_mv | AT xuj useofangiotensinconvertingenzymeinhibitorsandangiotensiniireceptorblockersincontextofcovid19outbreakaretrospectiveanalysis AT huangc useofangiotensinconvertingenzymeinhibitorsandangiotensiniireceptorblockersincontextofcovid19outbreakaretrospectiveanalysis AT fang useofangiotensinconvertingenzymeinhibitorsandangiotensiniireceptorblockersincontextofcovid19outbreakaretrospectiveanalysis AT liuz useofangiotensinconvertingenzymeinhibitorsandangiotensiniireceptorblockersincontextofcovid19outbreakaretrospectiveanalysis AT shangl useofangiotensinconvertingenzymeinhibitorsandangiotensiniireceptorblockersincontextofcovid19outbreakaretrospectiveanalysis AT zhouf useofangiotensinconvertingenzymeinhibitorsandangiotensiniireceptorblockersincontextofcovid19outbreakaretrospectiveanalysis AT wangy useofangiotensinconvertingenzymeinhibitorsandangiotensiniireceptorblockersincontextofcovid19outbreakaretrospectiveanalysis AT yuj useofangiotensinconvertingenzymeinhibitorsandangiotensiniireceptorblockersincontextofcovid19outbreakaretrospectiveanalysis AT yangl useofangiotensinconvertingenzymeinhibitorsandangiotensiniireceptorblockersincontextofcovid19outbreakaretrospectiveanalysis AT xiek useofangiotensinconvertingenzymeinhibitorsandangiotensiniireceptorblockersincontextofcovid19outbreakaretrospectiveanalysis AT huangz useofangiotensinconvertingenzymeinhibitorsandangiotensiniireceptorblockersincontextofcovid19outbreakaretrospectiveanalysis AT huangl useofangiotensinconvertingenzymeinhibitorsandangiotensiniireceptorblockersincontextofcovid19outbreakaretrospectiveanalysis AT gux useofangiotensinconvertingenzymeinhibitorsandangiotensiniireceptorblockersincontextofcovid19outbreakaretrospectiveanalysis AT lih useofangiotensinconvertingenzymeinhibitorsandangiotensiniireceptorblockersincontextofcovid19outbreakaretrospectiveanalysis AT zhangy useofangiotensinconvertingenzymeinhibitorsandangiotensiniireceptorblockersincontextofcovid19outbreakaretrospectiveanalysis AT wangy useofangiotensinconvertingenzymeinhibitorsandangiotensiniireceptorblockersincontextofcovid19outbreakaretrospectiveanalysis AT haydenfg useofangiotensinconvertingenzymeinhibitorsandangiotensiniireceptorblockersincontextofcovid19outbreakaretrospectiveanalysis AT horbypw useofangiotensinconvertingenzymeinhibitorsandangiotensiniireceptorblockersincontextofcovid19outbreakaretrospectiveanalysis AT caob useofangiotensinconvertingenzymeinhibitorsandangiotensiniireceptorblockersincontextofcovid19outbreakaretrospectiveanalysis AT wangc useofangiotensinconvertingenzymeinhibitorsandangiotensiniireceptorblockersincontextofcovid19outbreakaretrospectiveanalysis |